Quantitative findings across the corpus present a mixed picture with several statistically significant preclinical signals alongside null human results. In CorreiaMelo 2019, rapamycin treatment in nfκb1−/− mice yielded multiple significant differences across measured endpoints (P < 0.01 and P < 0.001 for several comparisons), indicating improvements in healthspan parameters. Translational relevance to humans remains uncertain. Elliehausen 2025 reported that intermittent rapamycin did not compromise physical performance or muscle hypertrophy while alleviating glucose disruptions. The systematic review by Shindyapina 2022 found that developmental rapamycin treatment was sufficient to extend lifespan in genetically diverse mice.

RESEARKA

Citation Support